Biohaven

We’re sharing preclinical data on our MoDE™ degrader in pemphigus vulgaris, a rare autoimmune skin disease, at the upcoming @AADmember Annual Meeting. Register here: bit.ly/3ZJ5X92 #AAD2026 #MedEd #DaysMatter

The @MichaelJFoxOrg Foundation is hosting its Parkinson’s IQ + You event in Nevada this weekend and our Chief Medical Officer will be speaking on the panel, “Exploring the Latest in Parkinson’s Research”, to share his perspective on the evolving landscape: bit.ly/4r9oKW8

Our CEO will join industry leaders at the R&D Leadership Summit for a discussion on how the industry can drive innovation and deliver transformative medicines balancing large-scale therapeutic opportunities with the growing potential of precision science: brnw.ch/21x0w1L

Our CEO will be participating in the @Yale Entrepreneurial Society Dinner this week, where he will share his journey through academic medicine, biotech entrepreneurship and the founding of Biohaven. #Yale #Entrepreneurship

Our Chief Translational Officer is presenting at the TD Cowen Health Care Conference sharing an update on our pipeline and the platform technologies driving it including our degrader, ion channel, oncology and myostatin programs. #DaysMatter #Investors #TDcowenHealthcare

The @US_FDA is hosting its virtual #RareDiseaseDay. The event will highlight their initiatives to advance medical product development for rare diseases, the use of real-world data and more. Patients, families, HCPs and advocates are encouraged to attend: bit.ly/4kHLo6l

Biohaven’s oncology leadership team will be participating in a fireside chat at @Citi’s 2026 Virtual Oncology Leadership Summit! We look forward to engaging with the community and contributing to the broader dialogue shaping the future of oncology. #DaysMatter #Oncology

The Clinical Research Center at @UConnHealth is among several clinical sites participating in our global trial evaluating an investigational therapy designed to target the root cause of IgA nephropathy, a rare kidney disease. Learn more about the study: brnw.ch/21x012E

We are dedicated to scientific innovation to treat and prevent the most challenging diseases and help improve lives. Guided by teamwork, collaboration and accountability, we work with urgency to push boundaries and help alleviate the burden of disease. Learn more: bit.ly/3JXoOZ9

This #WorldCancerDay—United by Unique—we center the real-world experiences behind every diagnosis. That’s why we’re committed to advancing innovative antibody-drug conjugate (ADC) research, guided by patients and driven by science, to help tackle some of the most challenging cancers. Learn more: biohaven.com/pipeline/

Our VP of Clinical Operations is sharing real-world perspectives across two @SCOPE_365 panels, covering what it takes to run smarter, more efficient clinical trials. Join us: brnw.ch/21wZApw #SCOPESummit #ClinicalTrials #ClinicalOperations #MergersAndAcquisitions

@Hu32274Hu Our global trial is looking to begin mid-year this year.

@biohaven The encouraging therapeutic effect. When will the global phase III clinical trial of bhv-1400 begin?

Our TRAP degrader in IgAN shows next- generation precision in action. First-in-patient dosing selectively lowered Gd-IgA1 within hours, with improvements in hematuria, proteinuria and eGFR within weeks: bit.ly/4aWxgTY #DaysMatter

At Biohaven, #DaysMatter. We’re dedicated to advancing science with the speed and rigor that patients expect and deserve. Explore our pipeline: bit.ly/4jOEmL8 #ClinicalResearch #DrugDevelopment

ICYMI: On @MadMoneyOnCNBC with @jimcramer, our CEO explained how our TRAP degrader is being applied in kidney disease (IgAN). Through precision immunology, we can selectively target disease-causing antibodies while leaving the healthy immune system intact. brnw.ch/21wZcLD

@JimCramer took a closer look at our pipeline on @MadMoneyOnCNBC with our CEO as they break down our progress in precision immunology, obesity and epilepsy and why #DaysMatter for patients waiting for new therapies. brnw.ch/21wZcM6 $BHVN #MadMoney #JimCramer #JPM26

Our CEO presented at the @JPMorgan Healthcare Conference, sharing updates on the diversified platforms in our pipeline including our degrader, myostatin and Kv7 programs. To view the presentation, visit: brnw.ch/21wZ9bg #JPM26 #DaysMatter

We kicked off JPM Week by hosting our annual event with @Yale and @yale_ventures! We’re energized by the New Haven life sciences community and their groundbreaking work that is moving therapies closer to the patients who need them most. #NewHaven #LifeSciences

Catch our CEO on @JimCramer’s @MadMoneyOnCNBC for a conversation spotlighting our vision, progress and what’s ahead. Tune in Wednesday at 6:00 PM EST on @CNBC: cnbc.com/mad-money/ $BHVN #MadMoney #JimCramer

Live from #JPM2026, our CEO joined @BradLoncar on @BiotechTVto discuss the momentum across our pipeline. The conversation highlighted progress in precision immunology, neurodegeneration, obesity and epilepsy. Tune in now: bit.ly/4sJ6Ewj #DaysMatter #Innovation